Fig. 1.
Bleomycin increases production of the levels of 2,3-dinor-6-keto-PGF1α in the urine and the lung. Transgenic mice that overexpress prostaglandin I2 synthase (PGIS OE+) and littermate control PGIS OE− mice were intranasally administered 0.08 U of bleomycin or PBS at day 0. A: 12–16 mice per treatment group were placed in metabolic cages, 4 mice per cage, and the mouse urine was collected daily from day −1 to day 12. B: lungs of bleomycin (bleo)- or PBS-treated mice were harvested at day 6 after bleomycin administration. The levels of 2,3-dinor-6-keto-PGF1α in the urine samples and in the lung homogenate were determined by a gas chromatographic-mass spectrometric assay. Data shown are the means ± SE, n = 3–4; each data point represents a urine sample collected from a cage of 4 mice (A) and n = 4–8 (B). *P < 0.05 vs. all 3 other groups at the same time point.